See more : Cospower Engineering Limited (COSPOWER.BO) Income Statement Analysis – Financial Results
Complete financial analysis of Orion Nutraceuticals Inc. (ORI.CN) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Orion Nutraceuticals Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- TAAT Global Alternatives Inc. (TOBAF) Income Statement Analysis – Financial Results
- Luceco plc (LUCE.L) Income Statement Analysis – Financial Results
- Glass House Brands Inc. (GHBWF) Income Statement Analysis – Financial Results
- Buzzi Unicem S.p.A. (BZU.MI) Income Statement Analysis – Financial Results
- Salon City, Inc. (SALN) Income Statement Analysis – Financial Results
Orion Nutraceuticals Inc. (ORI.CN)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.orionnutra.ca/
About Orion Nutraceuticals Inc.
Orion Nutraceuticals Inc. focuses on the drug for treating asthma and chronic obstructive pulmonary diseases in Canada. The company was formerly known as Cline Capital Corp. Orion Nutraceuticals Inc. was incorporated in 2017 and is headquartered in Vancouver, Canada.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 172.09K | 282.40K | 552.50K | 543.10K | 2.97M |
| Selling & Marketing | 0.00 | 107.60K | 0.00 | 0.00 | 0.00 | 60.00K |
| SG&A | 316.36K | 279.69K | 282.40K | 552.50K | 543.10K | 3.03M |
| Other Expenses | 0.00 | 0.00 | 5.78K | 20.00K | 156.85K | 146.25K |
| Operating Expenses | 316.36K | 279.69K | 282.40K | 552.50K | 543.10K | 3.03M |
| Cost & Expenses | 316.36K | 279.69K | 282.40K | 552.50K | 543.10K | 3.03M |
| Interest Income | 42.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 2.34M | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 254.54K | 0.00 | 2.34M | 206.30K | 171.86K | 161.14K |
| EBITDA | -61.82K | -279.69K | 2.06M | -882.93K | -386.24K | -6.39M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -316.36K | -279.69K | -282.40K | -202.06K | -699.95K | 325.71K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 254.54K | 0.00 | 267.62K | -350.44K | 313.71K | -3.50M |
| Income Before Tax | -61.82K | -279.69K | -2.62M | -882.94K | -386.24K | -6.39M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 2.34M | 350.44K | -156.85K | 6.72M |
| Net Income | -61.82K | -279.69K | -4.96M | -1.23M | -229.39K | -13.11M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | 0.00 | -0.01 | -0.17 | -0.05 | -0.12 | -7.52 |
| EPS Diluted | 0.00 | -0.01 | -0.17 | -0.05 | -0.12 | -7.52 |
| Weighted Avg Shares Out | 29.31M | 29.31M | 29.31M | 26.64M | 1.91M | 1.74M |
| Weighted Avg Shares Out (Dil) | 29.31M | 29.31M | 29.31M | 26.64M | 1.91M | 1.74M |
Source: https://incomestatements.info
Category: Stock Reports